...
首页> 外文期刊>Biopharmaceutics and Drug Disposition >Formulation and evaluation of chitosan microspheres of aceclofenac for colon-targeted drug delivery.
【24h】

Formulation and evaluation of chitosan microspheres of aceclofenac for colon-targeted drug delivery.

机译:醋氯芬酸壳聚糖微球用于结肠靶向药物递送的配方和评价。

获取原文
获取原文并翻译 | 示例

摘要

The objective of this investigation was to develop novel colon specific drug delivery. Aceclofenac, a NSAID, was successfully encapsulated into chitosan microspheres. Various formulations were prepared by varying the ratio of chitosan, span-85 and stirring speed and the amount of glutaraldehyde. The SEM study showed that microspheres have smooth surfaces. Microspheres were characterised by Fourier transform infrared (FTIR) spectroscopy and differential scanning calorimetry (DSC) to confirm the absence of chemical interactions between drug and polymer and to know the formation of microspheres structure. The microspheres were evaluated for particle size, encapsulation efficiency, drug loading capacity, mucoadhesion studies, stability studies, in vitro and in vivo drug release studies. Particle sizes, as measured by the laser light scattering technique, were of an average size in the range 41-80 microm. The swelling index was in the range 0.37-0.82 and the entrapment efficiency range was 51-75% for all the formulations. The optimised batch ACM(13) released 83.6% at 8 h and 104% at 24 h in SCF containing rat caecal content. Eudragit coated chitosan microspheres prevented the release of the aceclofenac in the physiological environment of the stomach and small intestine and released 95.9+/-0.34% in the colon. With regard to release kinetics, the data were best fitted with the Higuchi model and showed zero order release with non-Fickian diffusion mechanism. The in vivo findings suggest that aceclofenac microspheres exhibit a prolonged effect of aceclofenac in rats and produce a significant anti-inflammatory effect. The findings of the present study conclusively state that chitosan microspheres are promising for colon targeting of aceclofenac to synchronise with chronobiological symptoms of rheumatoid arthritis.
机译:该研究的目的是开发新颖的结肠特异性药物递送。 NSAID醋氯芬酸已成功封装到壳聚糖微球中。通过改变壳聚糖的比例,span-85,搅拌速度和戊二醛的量来制备各种制剂。 SEM研究表明,微球具有光滑的表面。通过傅立叶变换红外(FTIR)光谱和差示扫描量热法(DSC)对微球进行表征,以确认药物与聚合物之间不存在化学相互作用,并了解微球结构的形成。评价了微球的粒度,包封效率,药物负载能力,粘膜粘附研究,稳定性研究,体外和体内药物释放研究。通过激光散射技术测得的粒度的平均粒度为41-80微米。对于所有制剂,溶胀指数在0.37-0.82的范围内,并且包封效率范围为51-75%。优化的ACM(13)批次在含有大鼠盲肠成分的SCF中在8 h释放83.6%,在24 h释放104%。 Eudragit包被的壳聚糖微球阻止了胃和小肠生理环境中醋氯芬酸的释放,并在结肠中释放了95.9 +/- 0.34%。关于释放动力学,数据最适合Higuchi模型,并显示具有非菲克扩散机制的零级释放。体内发现表明醋氯芬酸微球在大鼠中显示醋氯芬酸的延长作用并产生显着的抗炎作用。本研究的发现最终表明,壳聚糖微球有望将醋氯芬酸用于结肠定位,以与类风湿关节炎的时间生物学症状同步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号